The predictTx platform is Imagen’s suite of in vitro pharmacology services for the drug discovery and development community. By harnessing the power of our biobank, with 100’s of clinically relevant 2D and 3D patient derived cell (PDC) models recapitulating the phenotype and genotype of parent tumours. We offer access to an unrivalled breadth of PDC models and related data, and can help you make rapid, informed decisions on which investigational compounds to progress.
Facilitate rapid drug discovery and development by screening your compounds on our PDC models.
Piggyback your compound on our routine PDC screen with models developed in real time as patients are referred to Imagen
Test your target hypothesis by selecting PDC models based on genomic data, patient treatment, or clinical history
Predict treatment sensitivity or resistance, optimise combination strategies, or identify biomarkers for your Phase I-III patients
Leverage Imagen’s global clinical network to develop unique, highly relevant/rare PDC model cohorts
The PDC models we develop come from a global clinical network that spans a broad demographic base.
Clinical history
Patient treatment history
Phenotypic drug response data to ~60 approved clinical drugs (including SOC)
NGS (WES and RNAseq)
Post-collection treatment responses
Our growing biobank of models is more than 90% accurate in predicting clinical response.
Our growing biobank of models is more than 90% accurate in predicting clinical response.
Find relevant therapies
Fresh tumour sample collected from patient, brought to our lab and developed into a PDC.
Around 60 drugs dosed on sample. Effects analysed using high-content screening. Results highlight suitable treatments and reported to oncologist.
PDC expanded and cryogenically preserved in Imagen biobank.
Rapid discovery and development of new therapies
Analyse data and generate endpoints (IC50’s, amongst others).
Re-derive and grow PDC models, dose according to protocol.
Agree objectives and select from 100’s of PDC models in our database (fully characterised, including WES/RNAseq).
Find relevant therapies
Fresh tumour sample collected from patient, brought to our lab and developed into a PDC.
Around 60 drugs dosed on sample. Effects analysed using high-content screening. Results highlight suitable treatments and reported to oncologist.
PDC expanded and cryogenically preserved in Imagen biobank.
Rapid discovery and development of new therapies
Agree objectives and select from 100’s of PDC models in our database (fully characterised, including WES/RNAseq).
Re-derive and grow PDC models, dose according to protocol.
Analyse data and generate endpoints (IC50’s, amongst others).
